239 related articles for article (PubMed ID: 36042691)
21. Oxaliplatin- and docetaxel-induced polyneuropathy: clinical and neurophysiological characteristics.
Bennedsgaard K; Ventzel L; Andersen NT; Themistocleous AC; Bennett DL; Jensen TS; Tankisi H; Finnerup NB
J Peripher Nerv Syst; 2020 Dec; 25(4):377-387. PubMed ID: 32902058
[TBL] [Abstract][Full Text] [Related]
22. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
[TBL] [Abstract][Full Text] [Related]
23. Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review.
Timmins HC; Mizrahi D; Li T; Kiernan MC; Goldstein D; Park SB
J Cancer Surviv; 2023 Feb; 17(1):222-236. PubMed ID: 33438175
[TBL] [Abstract][Full Text] [Related]
24. [Identification of biomarkers and new therapies for taxane-induced peripheral neuropathy].
Koyanagi M; Imai S; Nakagawa T; Matsubara K
Nihon Yakurigaku Zasshi; 2019; 154(5):241-244. PubMed ID: 31735751
[TBL] [Abstract][Full Text] [Related]
25. Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings.
Ibrahim EY; Ehrlich BE
Crit Rev Oncol Hematol; 2020 Jan; 145():102831. PubMed ID: 31783290
[TBL] [Abstract][Full Text] [Related]
26. Association between Genetic Variants and Peripheral Neuropathy in Patients with NSCLC Treated with First-Line Platinum-Based Therapy.
de Jong C; Herder GJM; van Haarlem SWA; van der Meer FS; van Lindert ASR; Ten Heuvel A; Brouwer J; Egberts TCG; Deneer VHM
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672910
[TBL] [Abstract][Full Text] [Related]
27. Mechanism-based Pharmacological Management of Chemotherapy-induced Neuropathic Pain from Preclinical Studies to Clinical Prospective: Platinum-based Drugs, Taxanes, and Vinca Alkaloids.
Zafari N; Velayati M; Maftooh M; Khazaei M; Nassiri M; Hassanian SM; Ghayour-Mobarhan M; Ferns GA; Avan A
Curr Pharm Des; 2023; 29(16):1245-1265. PubMed ID: 37190803
[TBL] [Abstract][Full Text] [Related]
28. Taxane-induced peripheral neuropathy: differences in patient report and objective assessment.
Timmins HC; Li T; Kiernan MC; Baron-Hay S; Marx G; Boyle F; Goldstein D; Park SB
Support Care Cancer; 2020 Sep; 28(9):4459-4466. PubMed ID: 31925531
[TBL] [Abstract][Full Text] [Related]
29. Impaired Postural Control and Altered Sensory Organization During Quiet Stance Following Neurotoxic Chemotherapy: A Preliminary Study.
Monfort SM; Pan X; Loprinzi CL; Lustberg MB; Chaudhari AMW
Integr Cancer Ther; 2019; 18():1534735419828823. PubMed ID: 30741022
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice.
Wickham R
Clin J Oncol Nurs; 2007 Jun; 11(3):361-76. PubMed ID: 17623621
[TBL] [Abstract][Full Text] [Related]
31. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
Amara S
Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011
[TBL] [Abstract][Full Text] [Related]
32. Assessment of chemotherapy-induced peripheral neuropathy using the LDIFLARE technique: a novel technique to detect neural small fiber dysfunction.
Sharma S; Venkitaraman R; Vas PR; Rayman G
Brain Behav; 2015 Jul; 5(7):e00354. PubMed ID: 26221574
[TBL] [Abstract][Full Text] [Related]
33. Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies.
Krøigård T; Schrøder HD; Qvortrup C; Eckhoff L; Pfeiffer P; Gaist D; Sindrup SH
Eur J Neurol; 2014 Apr; 21(4):623-9. PubMed ID: 24460946
[TBL] [Abstract][Full Text] [Related]
34. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
[TBL] [Abstract][Full Text] [Related]
35. Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy-induced peripheral neuropathy.
Khan Z; Jung M; Crow M; Mohindra R; Maiya V; Kaminker JS; Hackos DH; Chandler GS; McCarthy MI; Bhangale T
Genome Med; 2023 Jun; 15(1):45. PubMed ID: 37344884
[TBL] [Abstract][Full Text] [Related]
36. Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors.
Thomaier L; Darst BF; Jewett P; Hoffmann C; Brown K; Makaram A; Blaes A; Argenta P; Teoh D; Vogel RI
Gynecol Oncol; 2021 Dec; 163(3):578-582. PubMed ID: 34674889
[TBL] [Abstract][Full Text] [Related]
37. An evaluation of the effect of lithium on taxane-induced neuropathy.
Kochan DC; Novotny PJ; Cathcart-Rake EJ; Orme JJ; Tevaarwerk AJ; Ruddy KJ; Childs DS
Support Care Cancer; 2023 Apr; 31(5):299. PubMed ID: 37097406
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel.
Ventzel L; Jensen AB; Jensen AR; Jensen TS; Finnerup NB
Pain; 2016 Mar; 157(3):560-568. PubMed ID: 26529271
[TBL] [Abstract][Full Text] [Related]
39. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.
Chan A; Hertz DL; Morales M; Adams EJ; Gordon S; Tan CJ; Staff NP; Kamath J; Oh J; Shinde S; Pon D; Dixit N; D'Olimpio J; Dumitrescu C; Gobbo M; Kober K; Mayo S; Pang L; Subbiah I; Beutler AS; Peters KB; Loprinzi C; Lustberg MB
Support Care Cancer; 2019 Oct; 27(10):3729-3737. PubMed ID: 31363906
[TBL] [Abstract][Full Text] [Related]
40. Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy.
Hung HW; Liu CY; Chen HF; Chang CC; Chen SC
Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34073174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
